Pharmaceutical Market China

2,800.008,000.00

Published July 2015

Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 210 tables & figures within 188 pages.

Download Free Sample Pages here

Clear
SKU: N/A Category:

Description

Pharmaceutical Industry China  – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” (published July 2015) provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 210 tables & figures within 188 pages. For free sample pages download here

The Chinese biopharmaceutical market is presented as follows:

  • By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
  • By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

 

A wealth of financial information is provided including:

  • Company financials, sales & revenue figures 
  • China GDP, economic growth, export (bulk drug, formulations) figures
  • Indian health expenditure as a function of GDP
  • Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
  • Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
  • Projected figures of strategic emerging industry GDP percentage contribution

 

SWOT, Economic and Business Environment specifics include:

 

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Top Five Contract Pharmaceutical Export Markets of China
  • Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
  • Multinational penetration into the Chinese Pharma Market
  • Comprehensive product portfolios, R&D activity and pipeline therapeutics
  • M&A activity and future strategies of top Chinese pharmacos
  • Economic indicators, trade policy, merchandise and commercial trade statistics
  • Gross Domestic Product of China, historic and projection analysis
  • Chinese economic outlook in comparison to advanced economies
  • Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
  • Prescription drug sales distribution channels in China
  •  Major biogeneric products in China

 

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

 

• Amoytop Biotech

• Active Pharmaceutical Products

• Beijing Continent Pharmaceuticals

• FusoGen Pharmaceuticals

• Shanghai Huaguan Biochip

• SiBiono GeneTech

• Abbott

• AstraZeneca

• Boehringer Ingelheim

• Eli Lilly

• GlaxoSmithKline

• Johnson & Johnson Medical

• Merck

• Novartis

• Pfizer

• Roche

 

 

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

 

What you will gain:

 

  • An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
  • Current market facts, figures and product lines of key players in the industry
  • An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
  • Knowledge of how the Chinese pharma market will integrate into the global healthcare market
  • Information on key regulatory and government policies
  • Data on levels of private and publically funded biopharma studies in China
  • Strategies on how to adapt and restructure current business models to this industry

 

This report tackles key concerns to the Chinese biopharmaceutical market such as:

  • Lack of regulatory policy and legislation
  • Reimbursement schemes and payers concerns
  • Funding and government sponsorship issues
  • International skepticism of Chinese safety and efficacy therapeutic profiles

 

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

 

Reviews

There are no reviews yet.

Be the first to review “Pharmaceutical Market China”